Thursday, March 23, 2023
Treatment for multiple myeloma (MM) continues to rapidly evolve. There are now more active treatment regimens available for patients with MM, and new regimens are emerging. Patients are treated earlier, often with triplet and quadruplet combination regimens, and for longer periods of time. These changes have led to improved response rates, depth of response, disease-free intervals, and survival. There are many nuances to selecting therapy regimens for patients with MM. These educational programs tackle this rapidly evolving field and aid in development of optimal individualized care plans that take into consideration therapy-, disease-, and patient-specific factors.
Disclaimer
The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
Medscape Education© Medscape, LLC
Dr Shaji Kumar reviews the novel agents and strategies under investigation for the treatment of multiple myeloma.
What’s new in relapsed multiple myeloma? Hear Dr Ravi Vij summarize recent information.
Get expert insights in R/R multiple myeloma care.
